The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer

The histone methyltransferase G9a (EHMT2) is a key enzyme for dimethylation of lysine 9 at histone 3 (H3K9me2), a suppressive epigenetic mark. G9a is over-expressed in tumor cells and contributes to cancer aggressiveness. Biliary tract cancer (BTC) is a rare cancer with dismal prognosis due to a lac...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Human pathology 2018-02, Vol.72, p.117-126
Hauptverfasser:	Mayr, Christian, Helm, Katharina, Jakab, Martin, Ritter, Markus, Shrestha, Rajeev, Makaju, Ramesh, Wagner, Andrej, Pichler, Martin, Beyreis, Marlena, Staettner, Stefan, Jaeger, Tarkan, Klieser, Eckhard, Kiesslich, Tobias, Neureiter, Daniel
Format:	Artikel
Sprache:	eng
Schlagworte:	Biliary tract cancer Breast cancer Cancer therapies Cell culture Cholangiocarcinoma DNA methylation Epigenetics G9a Gallbladder Gene expression H3K9me2 Histone methyltransferase Immunoglobulins Lung cancer Medical prognosis Protein expression Proteins Stem cells
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!